FGFR3 INHIBITOR COMPOUNDS
To provide compounds and the like for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.SOLUTION: The prese...
Gespeichert in:
Hauptverfasser: | , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; jpn |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | DESTA DORO BUME TIMOTHY SCOTT KERCHER ANDREW KARL DILGER KEVIN RONALD CONDROSKI SHANE MICHAEL WALLS KAVERI BALAN URKALAN ANDREW TERRANCE METCALF ADEDOYIN DAVID ABRAHAM ROBERT ALAN HAZLITT |
description | To provide compounds and the like for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.SOLUTION: The present invention provides compounds of the formula below, or a pharmaceutically acceptable salt thereof (A: pyrazole, triazole or the like, substituted with R1 and R1A. X1, X2: N, C. X3: N, CH. X4: N, CR9. Y: NH, O, S, bond. Y1: bond, CHR7 or the like. Y2: bond, CHR3 or the like. Y3: CR4R5, CF2. Y4: CR3R4, CF2. Z: bond, CR4R4A or the like. Z1: bond, CH2, CH2CH2).SELECTED DRAWING: None
【課題】全身性硬化症、線維症(例えば、肺線維症)、軟骨無形成症、致死性骨異形成症(例えば、I型)、発育遅延及び黒色表皮腫を伴う重度の軟骨無形成症(SADDAN)、ムエンケ症候群、又はがんの治療に使用するための化合物等の提供。【解決手段】以下の式の化合物、又はその薬学的に許容される塩が提供される。TIFF2024099714000541.tif4196(式中、A:R1及びR1A置換のピラゾール、トリアゾールなど。X1、X2:N、C。X3:N、CH。X4:N、CR9。Y:NH、O、S、結合。Y1:結合、CHR7など。Y2:結合、CHR3など。Y3:CR4R5、CF2。Y4:CR3R4、CF2。Z:結合、CR4R4Aなど。Z1:結合、CH2、CH2CH2。)【選択図】なし |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2024099714A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2024099714A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2024099714A3</originalsourceid><addsrcrecordid>eNrjZJB0c3cLMlbw9PPwdPIM8Q9ScPb3DfAP9XMJ5mFgTUvMKU7lhdLcDEpuriHOHrqpBfnxqcUFicmpeakl8V4BRgZGJgaWluaGJo7GRCkCAFBbIHg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FGFR3 INHIBITOR COMPOUNDS</title><source>esp@cenet</source><creator>DESTA DORO BUME ; TIMOTHY SCOTT KERCHER ; ANDREW KARL DILGER ; KEVIN RONALD CONDROSKI ; SHANE MICHAEL WALLS ; KAVERI BALAN URKALAN ; ANDREW TERRANCE METCALF ; ADEDOYIN DAVID ABRAHAM ; ROBERT ALAN HAZLITT</creator><creatorcontrib>DESTA DORO BUME ; TIMOTHY SCOTT KERCHER ; ANDREW KARL DILGER ; KEVIN RONALD CONDROSKI ; SHANE MICHAEL WALLS ; KAVERI BALAN URKALAN ; ANDREW TERRANCE METCALF ; ADEDOYIN DAVID ABRAHAM ; ROBERT ALAN HAZLITT</creatorcontrib><description>To provide compounds and the like for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.SOLUTION: The present invention provides compounds of the formula below, or a pharmaceutically acceptable salt thereof (A: pyrazole, triazole or the like, substituted with R1 and R1A. X1, X2: N, C. X3: N, CH. X4: N, CR9. Y: NH, O, S, bond. Y1: bond, CHR7 or the like. Y2: bond, CHR3 or the like. Y3: CR4R5, CF2. Y4: CR3R4, CF2. Z: bond, CR4R4A or the like. Z1: bond, CH2, CH2CH2).SELECTED DRAWING: None
【課題】全身性硬化症、線維症(例えば、肺線維症)、軟骨無形成症、致死性骨異形成症(例えば、I型)、発育遅延及び黒色表皮腫を伴う重度の軟骨無形成症(SADDAN)、ムエンケ症候群、又はがんの治療に使用するための化合物等の提供。【解決手段】以下の式の化合物、又はその薬学的に許容される塩が提供される。TIFF2024099714000541.tif4196(式中、A:R1及びR1A置換のピラゾール、トリアゾールなど。X1、X2:N、C。X3:N、CH。X4:N、CR9。Y:NH、O、S、結合。Y1:結合、CHR7など。Y2:結合、CHR3など。Y3:CR4R5、CF2。Y4:CR3R4、CF2。Z:結合、CR4R4Aなど。Z1:結合、CH2、CH2CH2。)【選択図】なし</description><language>eng ; jpn</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240725&DB=EPODOC&CC=JP&NR=2024099714A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240725&DB=EPODOC&CC=JP&NR=2024099714A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DESTA DORO BUME</creatorcontrib><creatorcontrib>TIMOTHY SCOTT KERCHER</creatorcontrib><creatorcontrib>ANDREW KARL DILGER</creatorcontrib><creatorcontrib>KEVIN RONALD CONDROSKI</creatorcontrib><creatorcontrib>SHANE MICHAEL WALLS</creatorcontrib><creatorcontrib>KAVERI BALAN URKALAN</creatorcontrib><creatorcontrib>ANDREW TERRANCE METCALF</creatorcontrib><creatorcontrib>ADEDOYIN DAVID ABRAHAM</creatorcontrib><creatorcontrib>ROBERT ALAN HAZLITT</creatorcontrib><title>FGFR3 INHIBITOR COMPOUNDS</title><description>To provide compounds and the like for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.SOLUTION: The present invention provides compounds of the formula below, or a pharmaceutically acceptable salt thereof (A: pyrazole, triazole or the like, substituted with R1 and R1A. X1, X2: N, C. X3: N, CH. X4: N, CR9. Y: NH, O, S, bond. Y1: bond, CHR7 or the like. Y2: bond, CHR3 or the like. Y3: CR4R5, CF2. Y4: CR3R4, CF2. Z: bond, CR4R4A or the like. Z1: bond, CH2, CH2CH2).SELECTED DRAWING: None
【課題】全身性硬化症、線維症(例えば、肺線維症)、軟骨無形成症、致死性骨異形成症(例えば、I型)、発育遅延及び黒色表皮腫を伴う重度の軟骨無形成症(SADDAN)、ムエンケ症候群、又はがんの治療に使用するための化合物等の提供。【解決手段】以下の式の化合物、又はその薬学的に許容される塩が提供される。TIFF2024099714000541.tif4196(式中、A:R1及びR1A置換のピラゾール、トリアゾールなど。X1、X2:N、C。X3:N、CH。X4:N、CR9。Y:NH、O、S、結合。Y1:結合、CHR7など。Y2:結合、CHR3など。Y3:CR4R5、CF2。Y4:CR3R4、CF2。Z:結合、CR4R4Aなど。Z1:結合、CH2、CH2CH2。)【選択図】なし</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB0c3cLMlbw9PPwdPIM8Q9ScPb3DfAP9XMJ5mFgTUvMKU7lhdLcDEpuriHOHrqpBfnxqcUFicmpeakl8V4BRgZGJgaWluaGJo7GRCkCAFBbIHg</recordid><startdate>20240725</startdate><enddate>20240725</enddate><creator>DESTA DORO BUME</creator><creator>TIMOTHY SCOTT KERCHER</creator><creator>ANDREW KARL DILGER</creator><creator>KEVIN RONALD CONDROSKI</creator><creator>SHANE MICHAEL WALLS</creator><creator>KAVERI BALAN URKALAN</creator><creator>ANDREW TERRANCE METCALF</creator><creator>ADEDOYIN DAVID ABRAHAM</creator><creator>ROBERT ALAN HAZLITT</creator><scope>EVB</scope></search><sort><creationdate>20240725</creationdate><title>FGFR3 INHIBITOR COMPOUNDS</title><author>DESTA DORO BUME ; TIMOTHY SCOTT KERCHER ; ANDREW KARL DILGER ; KEVIN RONALD CONDROSKI ; SHANE MICHAEL WALLS ; KAVERI BALAN URKALAN ; ANDREW TERRANCE METCALF ; ADEDOYIN DAVID ABRAHAM ; ROBERT ALAN HAZLITT</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2024099714A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>DESTA DORO BUME</creatorcontrib><creatorcontrib>TIMOTHY SCOTT KERCHER</creatorcontrib><creatorcontrib>ANDREW KARL DILGER</creatorcontrib><creatorcontrib>KEVIN RONALD CONDROSKI</creatorcontrib><creatorcontrib>SHANE MICHAEL WALLS</creatorcontrib><creatorcontrib>KAVERI BALAN URKALAN</creatorcontrib><creatorcontrib>ANDREW TERRANCE METCALF</creatorcontrib><creatorcontrib>ADEDOYIN DAVID ABRAHAM</creatorcontrib><creatorcontrib>ROBERT ALAN HAZLITT</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DESTA DORO BUME</au><au>TIMOTHY SCOTT KERCHER</au><au>ANDREW KARL DILGER</au><au>KEVIN RONALD CONDROSKI</au><au>SHANE MICHAEL WALLS</au><au>KAVERI BALAN URKALAN</au><au>ANDREW TERRANCE METCALF</au><au>ADEDOYIN DAVID ABRAHAM</au><au>ROBERT ALAN HAZLITT</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FGFR3 INHIBITOR COMPOUNDS</title><date>2024-07-25</date><risdate>2024</risdate><abstract>To provide compounds and the like for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.SOLUTION: The present invention provides compounds of the formula below, or a pharmaceutically acceptable salt thereof (A: pyrazole, triazole or the like, substituted with R1 and R1A. X1, X2: N, C. X3: N, CH. X4: N, CR9. Y: NH, O, S, bond. Y1: bond, CHR7 or the like. Y2: bond, CHR3 or the like. Y3: CR4R5, CF2. Y4: CR3R4, CF2. Z: bond, CR4R4A or the like. Z1: bond, CH2, CH2CH2).SELECTED DRAWING: None
【課題】全身性硬化症、線維症(例えば、肺線維症)、軟骨無形成症、致死性骨異形成症(例えば、I型)、発育遅延及び黒色表皮腫を伴う重度の軟骨無形成症(SADDAN)、ムエンケ症候群、又はがんの治療に使用するための化合物等の提供。【解決手段】以下の式の化合物、又はその薬学的に許容される塩が提供される。TIFF2024099714000541.tif4196(式中、A:R1及びR1A置換のピラゾール、トリアゾールなど。X1、X2:N、C。X3:N、CH。X4:N、CR9。Y:NH、O、S、結合。Y1:結合、CHR7など。Y2:結合、CHR3など。Y3:CR4R5、CF2。Y4:CR3R4、CF2。Z:結合、CR4R4Aなど。Z1:結合、CH2、CH2CH2。)【選択図】なし</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; jpn |
recordid | cdi_epo_espacenet_JP2024099714A |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | FGFR3 INHIBITOR COMPOUNDS |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T09%3A58%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DESTA%20DORO%20BUME&rft.date=2024-07-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2024099714A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |